Disease Overview
Multiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability.
Although the etiology of MS is uncertain, it is thought to involve genetic, environmental, and infectious disease components. Current therapies for MS largely fall into two categories: symptomatic and disease-modifying, and both are frequently used in combination with one another.
Market Snapshot
Multiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability.
Although the etiology of MS is uncertain, it is thought to involve genetic, environmental, and infectious disease components. Current therapies for MS largely fall into two categories: symptomatic and disease-modifying, and both are frequently used in combination with one another.
Market Snapshot
- Ocrevus’s peak sales estimate increases as early data suggest it is competing across a range of treatment settings.
- Despite the approvals of newer, more efficacious therapies, Copaxone and interferon beta remain key components of treatment practices in MS.
- Despite negative population growth in some markets, an overall increase in diagnosed prevalent cases of MS is expected.
- Exciting newcomer Ocrevus is gaining considerable traction in only its first year of commercial availability.
- Celgene must balance ozanimod pricing to maximize MS opportunity while ensuring reimbursement in secondary indications.
- Products targeting progressive disease types will have favorable reimbursement.
Table of Contents
FORECAST: MULTIPLE SCLEROSIS (Published on 24 November 2017)
Overview
Executive Summary
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile (Late Stage): Alks 8700
Product Profile: Aubagio
Product Profile: Avonex
Product Profile: Betaseron
Product Profile: Copaxone
Product Profile: Gilenya
Product Profile: Lemtrada
Product Profile: Mavenclad
Product Profile: Ocrevus
Product Profile: Plegridy
Product Profile: Rebif
Product Profile: Tecfidera
Product Profile: Tysabri
Product Profile: Zinbryta
Product Profile (Late Stage): Ofatumumab
Product Profile (Late Stage): Ozanimod
Product Profile (Late Stage): Ponesimod
Product Profile (Late Stage): Siponimod
Product Profile (Late Stage): Ublituximab
Executive Summary
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile (Late Stage): Alks 8700
Product Profile: Aubagio
Product Profile: Avonex
Product Profile: Betaseron
Product Profile: Copaxone
Product Profile: Gilenya
Product Profile: Lemtrada
Product Profile: Mavenclad
Product Profile: Ocrevus
Product Profile: Plegridy
Product Profile: Rebif
Product Profile: Tecfidera
Product Profile: Tysabri
Product Profile: Zinbryta
Product Profile (Late Stage): Ofatumumab
Product Profile (Late Stage): Ozanimod
Product Profile (Late Stage): Ponesimod
Product Profile (Late Stage): Siponimod
Product Profile (Late Stage): Ublituximab
TREATMENT: MULTIPLE SCLEROSIS (Published on 17 November 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Multiple Sclerosis
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Multiple Sclerosis
EPIDEMIOLOGY: MULTIPLE SCLEROSIS (Published on 18 July 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: MULTIPLE SCLEROSIS (Published on 24 November 2017)
Overview
Executive Summary
Product Overview
Product Profile: Aubagio
Product Profile: Avonex
Product Profile: Betaseron
Product Profile: Copaxone
Product Profile: Gilenya
Product Profile: Lemtrada
Product Profile: Mavenclad
Product Profile: Ocrevus
Product Profile: Plegridy
Product Profile: Rebif
Product Profile: Tecfidera
Product Profile: Tysabri
Product Profile: Zinbryta
Executive Summary
Product Overview
Product Profile: Aubagio
Product Profile: Avonex
Product Profile: Betaseron
Product Profile: Copaxone
Product Profile: Gilenya
Product Profile: Lemtrada
Product Profile: Mavenclad
Product Profile: Ocrevus
Product Profile: Plegridy
Product Profile: Rebif
Product Profile: Tecfidera
Product Profile: Tysabri
Product Profile: Zinbryta
MULTIPLE SCLEROSIS PRICING, REIMBURSEMENT, AND ACCESS (Published on 25 July 2017)
Overview
Executive Summary
Regulatory Labels
Global Access Levers
Evidence And Value
Access To Recently Approved And Pipeline Products
Pricing
Us
Japan
France
Germany
Italy
Spain
Uk
Methodology
Executive Summary
Regulatory Labels
Global Access Levers
Evidence And Value
Access To Recently Approved And Pipeline Products
Pricing
Us
Japan
France
Germany
Italy
Spain
Uk
Methodology
PIPELINE: MULTIPLE SCLEROSIS (Published on 24 November 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Alks 8700
Product Profile (Late Stage): Ofatumumab
Product Profile (Late Stage): Ozanimod
Product Profile (Late Stage): Ponesimod
Product Profile (Late Stage): Siponimod
Product Profile (Late Stage): Ublituximab
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Alks 8700
Product Profile (Late Stage): Ofatumumab
Product Profile (Late Stage): Ozanimod
Product Profile (Late Stage): Ponesimod
Product Profile (Late Stage): Siponimod
Product Profile (Late Stage): Ublituximab
LIST OF FIGURES
Figure 1: Multiple sclerosis – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for multiple sclerosis
Figure 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Growth dynamics of the multiple sclerosis market across the US, Japan, and five major EU markets, by country, 2016–25
Figure 5: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype, 2016–25
Figure 6: Methodology flow for The authors multiple sclerosis forecast
Figure 7: Price sources and calculations, by country
Figure 8: ALKS 8700 for multiple sclerosis – SWOT analysis
Figure 9: The authors drug assessment summary of ALKS 8700 for multiple sclerosis
Figure 10: The authors drug assessment summary of ALKS 8700 for multiple sclerosis
Figure 11: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 12: Aubagio for multiple sclerosis – SWOT analysis
Figure 13: The authors drug assessment summary for Aubagio in multiple sclerosis
Figure 14: The authors drug assessment summary for Aubagio in multiple sclerosis
Figure 15: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Avonex for multiple sclerosis – SWOT analysis
Figure 17: The authors drug assessment summary for Avonex in multiple sclerosis
Figure 18: The authors drug assessment summary for Avonex in multiple sclerosis
Figure 19: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 20: Betaseron for multiple sclerosis – SWOT analysis
Figure 21: The authors drug assessment summary for Betaseron in multiple sclerosis
Figure 22: The authors drug assessment summary for Betaseron in multiple sclerosis
Figure 23: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 24: Copaxone for multiple sclerosis – SWOT analysis
Figure 25: The authors drug assessment summary for Copaxone in multiple sclerosis
Figure 26: The authors drug assessment summary for Copaxone in multiple sclerosis
Figure 27: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 28: Gilenya for multiple sclerosis – SWOT analysis
Figure 29: The authors drug assessment summary for Gilenya in multiple sclerosis
Figure 30: The authors drug assessment summary for Gilenya in multiple sclerosis
Figure 31: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 32: Lemtrada for multiple sclerosis – SWOT analysis
Figure 33: The authors drug assessment summary for Lemtrada in multiple sclerosis
Figure 34: The authors drug assessment summary for Lemtrada in multiple sclerosis
Figure 35: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 36: Mavenclad for multiple sclerosis – SWOT analysis
Figure 37: The authors drug assessment summary for Mavenclad in multiple sclerosis
Figure 38: The authors drug assessment summary for cladribine in multiple sclerosis
Figure 39: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 40: Ocrevus for multiple sclerosis – SWOT analysis
Figure 41: The authors drug assessment summary for Ocrevus in multiple sclerosis
Figure 42: The authors drug assessment summary for Ocrevus in multiple sclerosis
Figure 43: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 44: Plegridy for multiple sclerosis – SWOT analysis
Figure 45: The authors drug assessment summary for Plegridy in multiple sclerosis
Figure 46: The authors drug assessment summary for Plegridy in multiple sclerosis
Figure 47: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 48: Rebif for multiple sclerosis – SWOT analysis
Figure 49: The authors drug assessment summary for Rebif in multiple sclerosis
Figure 50: The authors drug assessment summary for Rebif in multiple sclerosis
Figure 51: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 52: Tecfidera for multiple sclerosis – SWOT analysis
Figure 53: The authors drug assessment summary for Tecfidera in multiple sclerosis
Figure 54: The authors drug assessment summary for Tecfidera in multiple sclerosis
Figure 55: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 56: Tysabri for multiple sclerosis – SWOT analysis
Figure 57: The authors drug assessment summary for Tysabri in multiple sclerosis
Figure 58: The authors drug assessment summary for Tysabri in multiple sclerosis
Figure 59: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 60: Zinbryta for multiple sclerosis – SWOT analysis
Figure 61: The authors drug assessment summary for Zinbryta in multiple sclerosis
Figure 62: The authors drug assessment summary for Zinbryta in multiple sclerosis
Figure 63: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 64: Ofatumumab for multiple sclerosis – SWOT analysis
Figure 65: The authors drug assessment summary of ofatumumab for multiple sclerosis
Figure 66: The authors drug assessment summary of ofatumumab for multiple sclerosis
Figure 67: Ozanimod for multiple sclerosis – SWOT analysis
Figure 68: The authors drug assessment summary of ozanimod for multiple sclerosis
Figure 69: The authors drug assessment summary of ozanimod for multiple sclerosis
Figure 70: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 71: Ponesimod for multiple sclerosis – SWOT analysis
Figure 72: The authors drug assessment summary of ponesimod for multiple sclerosis
Figure 73: The authors drug assessment summary of ponesimod for multiple sclerosis
Figure 74: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 75: Siponimod for multiple sclerosis – SWOT analysis
Figure 76: The authors drug assessment summary of siponimod for multiple sclerosis
Figure 77: The authors drug assessment summary of siponimod for multiple sclerosis
Figure 78: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 79: Ublituximab for multiple sclerosis – SWOT analysis
Figure 80: The authors drug assessment summary of ublituximab for multiple sclerosis
Figure 81: The authors drug assessment summary of ublituximab for multiple sclerosis
Figure 82: Disability accumulation in the three main clinical subtypes of multiple sclerosis
Figure 83: Segmentation of respondents’ multiple sclerosis patients in the US, Japan, and five major EU markets, by disease subtype, 2016
Figure 84: RRMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
Figure 85: PPMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
Figure 86: SPMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
Figure 87: Use of monotherapy or combination regimens of disease-modifying drugs, by disease subtype and line of therapy, 2016
Figure 88: Top five disease-modifying therapies used at first line in RRMS patients in the US, Japan, and five major EU markets, by country
Figure 89: Top five disease-modifying therapies used at second line and later in RRMS patients in the US, Japan, and five major EU markets, by country
Figure 90: Top five disease-modifying therapies used at first line in PPMS patients in the US, Japan, and five major EU markets, by country
Figure 91: Top five disease-modifying therapies used at second line and later in PPMS patients in the US, Japan, and five major EU markets, by country
Figure 92: Top five disease-modifying therapies used at first line in SPMS patients in the US, Japan, and five major EU markets, by country
Figure 93: Top five disease-modifying therapies used at second line and later in SPMS patients in the US, Japan, and five major EU markets, by country
Figure 94: Average compliance rates with disease-modifying therapies, by disease subtype and drug administration route, 2016
Figure 95: Key unmet needs in multiple sclerosis across the US, Japan, and five major EU markets, 2016
Figure 96: Trends in diagnosed prevalent cases of MS in the US, Japan, and five major EU markets, 2017–37
Figure 97: Aubagio for multiple sclerosis – SWOT analysis
Figure 98: The authors drug assessment summary for Aubagio in multiple sclerosis
Figure 99: The authors drug assessment summary for Aubagio in multiple sclerosis
Figure 100: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 101: Avonex for multiple sclerosis – SWOT analysis
Figure 102: The authors drug assessment summary for Avonex in multiple sclerosis
Figure 103: The authors drug assessment summary for Avonex in multiple sclerosis
Figure 104: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 105: Betaseron for multiple sclerosis – SWOT analysis
Figure 106: The authors drug assessment summary for Betaseron in multiple sclerosis
Figure 107: The authors drug assessment summary for Betaseron in multiple sclerosis
Figure 108: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 109: Copaxone for multiple sclerosis – SWOT analysis
Figure 110: The authors drug assessment summary for Copaxone in multiple sclerosis
Figure 111: The authors drug assessment summary for Copaxone in multiple sclerosis
Figure 112: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 113: Gilenya for multiple sclerosis – SWOT analysis
Figure 114: The authors drug assessment summary for Gilenya in multiple sclerosis
Figure 115: The authors drug assessment summary for Gilenya in multiple sclerosis
Figure 116: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 117: Lemtrada for multiple sclerosis – SWOT analysis
Figure 118: The authors drug assessment summary for Lemtrada in multiple sclerosis
Figure 119: The authors drug assessment summary for Lemtrada in multiple sclerosis
Figure 120: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 121: Mavenclad for multiple sclerosis – SWOT analysis
Figure 122: The authors drug assessment summary for Mavenclad in multiple sclerosis
Figure 123: The authors drug assessment summary for cladribine in multiple sclerosis
Figure 124: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 125: Ocrevus for multiple sclerosis – SWOT analysis
Figure 126: The authors drug assessment summary for Ocrevus in multiple sclerosis
Figure 127: The authors drug assessment summary for Ocrevus in multiple sclerosis
Figure 128: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 129: Plegridy for multiple sclerosis – SWOT analysis
Figure 130: The authors drug assessment summary for Plegridy in multiple sclerosis
Figure 131: The authors drug assessment summary for Plegridy in multiple sclerosis
Figure 132: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 133: Rebif for multiple sclerosis – SWOT analysis
Figure 134: The authors drug assessment summary for Rebif in multiple sclerosis
Figure 135: The authors drug assessment summary for Rebif in multiple sclerosis
Figure 136: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 137: Tecfidera for multiple sclerosis – SWOT analysis
Figure 138: The authors drug assessment summary for Tecfidera in multiple sclerosis
Figure 139: The authors drug assessment summary for Tecfidera in multiple sclerosis
Figure 140: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 141: Tysabri for multiple sclerosis – SWOT analysis
Figure 142: The authors drug assessment summary for Tysabri in multiple sclerosis
Figure 143: The authors drug assessment summary for Tysabri in multiple sclerosis
Figure 144: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 145: Zinbryta for multiple sclerosis – SWOT analysis
Figure 146: The authors drug assessment summary for Zinbryta in multiple sclerosis
Figure 147: The authors drug assessment summary for Zinbryta in multiple sclerosis
Figure 148: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 149: ALKS 8700 for multiple sclerosis – SWOT analysis
Figure 150: The authors drug assessment summary of ALKS 8700 for multiple sclerosis
Figure 151: The authors drug assessment summary of ALKS 8700 for multiple sclerosis
Figure 152: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 153: Ofatumumab for multiple sclerosis – SWOT analysis
Figure 154: The authors drug assessment summary of ofatumumab for multiple sclerosis
Figure 155: The authors drug assessment summary of ofatumumab for multiple sclerosis
Figure 156: Ozanimod for multiple sclerosis – SWOT analysis
Figure 157: The authors drug assessment summary of ozanimod for multiple sclerosis
Figure 158: The authors drug assessment summary of ozanimod for multiple sclerosis
Figure 159: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 160: Ponesimod for multiple sclerosis – SWOT analysis
Figure 161: The authors drug assessment summary of ponesimod for multiple sclerosis
Figure 162: The authors drug assessment summary of ponesimod for multiple sclerosis
Figure 163: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 164: Siponimod for multiple sclerosis – SWOT analysis
Figure 165: The authors drug assessment summary of siponimod for multiple sclerosis
Figure 166: The authors drug assessment summary of siponimod for multiple sclerosis
Figure 167: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 168: Ublituximab for multiple sclerosis – SWOT analysis
Figure 169: The authors drug assessment summary of ublituximab for multiple sclerosis
Figure 170: The authors drug assessment summary of ublituximab for multiple sclerosis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for multiple sclerosis
Figure 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Growth dynamics of the multiple sclerosis market across the US, Japan, and five major EU markets, by country, 2016–25
Figure 5: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype, 2016–25
Figure 6: Methodology flow for The authors multiple sclerosis forecast
Figure 7: Price sources and calculations, by country
Figure 8: ALKS 8700 for multiple sclerosis – SWOT analysis
Figure 9: The authors drug assessment summary of ALKS 8700 for multiple sclerosis
Figure 10: The authors drug assessment summary of ALKS 8700 for multiple sclerosis
Figure 11: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 12: Aubagio for multiple sclerosis – SWOT analysis
Figure 13: The authors drug assessment summary for Aubagio in multiple sclerosis
Figure 14: The authors drug assessment summary for Aubagio in multiple sclerosis
Figure 15: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Avonex for multiple sclerosis – SWOT analysis
Figure 17: The authors drug assessment summary for Avonex in multiple sclerosis
Figure 18: The authors drug assessment summary for Avonex in multiple sclerosis
Figure 19: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 20: Betaseron for multiple sclerosis – SWOT analysis
Figure 21: The authors drug assessment summary for Betaseron in multiple sclerosis
Figure 22: The authors drug assessment summary for Betaseron in multiple sclerosis
Figure 23: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 24: Copaxone for multiple sclerosis – SWOT analysis
Figure 25: The authors drug assessment summary for Copaxone in multiple sclerosis
Figure 26: The authors drug assessment summary for Copaxone in multiple sclerosis
Figure 27: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 28: Gilenya for multiple sclerosis – SWOT analysis
Figure 29: The authors drug assessment summary for Gilenya in multiple sclerosis
Figure 30: The authors drug assessment summary for Gilenya in multiple sclerosis
Figure 31: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 32: Lemtrada for multiple sclerosis – SWOT analysis
Figure 33: The authors drug assessment summary for Lemtrada in multiple sclerosis
Figure 34: The authors drug assessment summary for Lemtrada in multiple sclerosis
Figure 35: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 36: Mavenclad for multiple sclerosis – SWOT analysis
Figure 37: The authors drug assessment summary for Mavenclad in multiple sclerosis
Figure 38: The authors drug assessment summary for cladribine in multiple sclerosis
Figure 39: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 40: Ocrevus for multiple sclerosis – SWOT analysis
Figure 41: The authors drug assessment summary for Ocrevus in multiple sclerosis
Figure 42: The authors drug assessment summary for Ocrevus in multiple sclerosis
Figure 43: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 44: Plegridy for multiple sclerosis – SWOT analysis
Figure 45: The authors drug assessment summary for Plegridy in multiple sclerosis
Figure 46: The authors drug assessment summary for Plegridy in multiple sclerosis
Figure 47: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 48: Rebif for multiple sclerosis – SWOT analysis
Figure 49: The authors drug assessment summary for Rebif in multiple sclerosis
Figure 50: The authors drug assessment summary for Rebif in multiple sclerosis
Figure 51: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 52: Tecfidera for multiple sclerosis – SWOT analysis
Figure 53: The authors drug assessment summary for Tecfidera in multiple sclerosis
Figure 54: The authors drug assessment summary for Tecfidera in multiple sclerosis
Figure 55: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 56: Tysabri for multiple sclerosis – SWOT analysis
Figure 57: The authors drug assessment summary for Tysabri in multiple sclerosis
Figure 58: The authors drug assessment summary for Tysabri in multiple sclerosis
Figure 59: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 60: Zinbryta for multiple sclerosis – SWOT analysis
Figure 61: The authors drug assessment summary for Zinbryta in multiple sclerosis
Figure 62: The authors drug assessment summary for Zinbryta in multiple sclerosis
Figure 63: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 64: Ofatumumab for multiple sclerosis – SWOT analysis
Figure 65: The authors drug assessment summary of ofatumumab for multiple sclerosis
Figure 66: The authors drug assessment summary of ofatumumab for multiple sclerosis
Figure 67: Ozanimod for multiple sclerosis – SWOT analysis
Figure 68: The authors drug assessment summary of ozanimod for multiple sclerosis
Figure 69: The authors drug assessment summary of ozanimod for multiple sclerosis
Figure 70: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 71: Ponesimod for multiple sclerosis – SWOT analysis
Figure 72: The authors drug assessment summary of ponesimod for multiple sclerosis
Figure 73: The authors drug assessment summary of ponesimod for multiple sclerosis
Figure 74: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 75: Siponimod for multiple sclerosis – SWOT analysis
Figure 76: The authors drug assessment summary of siponimod for multiple sclerosis
Figure 77: The authors drug assessment summary of siponimod for multiple sclerosis
Figure 78: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 79: Ublituximab for multiple sclerosis – SWOT analysis
Figure 80: The authors drug assessment summary of ublituximab for multiple sclerosis
Figure 81: The authors drug assessment summary of ublituximab for multiple sclerosis
Figure 82: Disability accumulation in the three main clinical subtypes of multiple sclerosis
Figure 83: Segmentation of respondents’ multiple sclerosis patients in the US, Japan, and five major EU markets, by disease subtype, 2016
Figure 84: RRMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
Figure 85: PPMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
Figure 86: SPMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
Figure 87: Use of monotherapy or combination regimens of disease-modifying drugs, by disease subtype and line of therapy, 2016
Figure 88: Top five disease-modifying therapies used at first line in RRMS patients in the US, Japan, and five major EU markets, by country
Figure 89: Top five disease-modifying therapies used at second line and later in RRMS patients in the US, Japan, and five major EU markets, by country
Figure 90: Top five disease-modifying therapies used at first line in PPMS patients in the US, Japan, and five major EU markets, by country
Figure 91: Top five disease-modifying therapies used at second line and later in PPMS patients in the US, Japan, and five major EU markets, by country
Figure 92: Top five disease-modifying therapies used at first line in SPMS patients in the US, Japan, and five major EU markets, by country
Figure 93: Top five disease-modifying therapies used at second line and later in SPMS patients in the US, Japan, and five major EU markets, by country
Figure 94: Average compliance rates with disease-modifying therapies, by disease subtype and drug administration route, 2016
Figure 95: Key unmet needs in multiple sclerosis across the US, Japan, and five major EU markets, 2016
Figure 96: Trends in diagnosed prevalent cases of MS in the US, Japan, and five major EU markets, 2017–37
Figure 97: Aubagio for multiple sclerosis – SWOT analysis
Figure 98: The authors drug assessment summary for Aubagio in multiple sclerosis
Figure 99: The authors drug assessment summary for Aubagio in multiple sclerosis
Figure 100: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 101: Avonex for multiple sclerosis – SWOT analysis
Figure 102: The authors drug assessment summary for Avonex in multiple sclerosis
Figure 103: The authors drug assessment summary for Avonex in multiple sclerosis
Figure 104: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 105: Betaseron for multiple sclerosis – SWOT analysis
Figure 106: The authors drug assessment summary for Betaseron in multiple sclerosis
Figure 107: The authors drug assessment summary for Betaseron in multiple sclerosis
Figure 108: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 109: Copaxone for multiple sclerosis – SWOT analysis
Figure 110: The authors drug assessment summary for Copaxone in multiple sclerosis
Figure 111: The authors drug assessment summary for Copaxone in multiple sclerosis
Figure 112: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 113: Gilenya for multiple sclerosis – SWOT analysis
Figure 114: The authors drug assessment summary for Gilenya in multiple sclerosis
Figure 115: The authors drug assessment summary for Gilenya in multiple sclerosis
Figure 116: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 117: Lemtrada for multiple sclerosis – SWOT analysis
Figure 118: The authors drug assessment summary for Lemtrada in multiple sclerosis
Figure 119: The authors drug assessment summary for Lemtrada in multiple sclerosis
Figure 120: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 121: Mavenclad for multiple sclerosis – SWOT analysis
Figure 122: The authors drug assessment summary for Mavenclad in multiple sclerosis
Figure 123: The authors drug assessment summary for cladribine in multiple sclerosis
Figure 124: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 125: Ocrevus for multiple sclerosis – SWOT analysis
Figure 126: The authors drug assessment summary for Ocrevus in multiple sclerosis
Figure 127: The authors drug assessment summary for Ocrevus in multiple sclerosis
Figure 128: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 129: Plegridy for multiple sclerosis – SWOT analysis
Figure 130: The authors drug assessment summary for Plegridy in multiple sclerosis
Figure 131: The authors drug assessment summary for Plegridy in multiple sclerosis
Figure 132: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 133: Rebif for multiple sclerosis – SWOT analysis
Figure 134: The authors drug assessment summary for Rebif in multiple sclerosis
Figure 135: The authors drug assessment summary for Rebif in multiple sclerosis
Figure 136: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 137: Tecfidera for multiple sclerosis – SWOT analysis
Figure 138: The authors drug assessment summary for Tecfidera in multiple sclerosis
Figure 139: The authors drug assessment summary for Tecfidera in multiple sclerosis
Figure 140: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 141: Tysabri for multiple sclerosis – SWOT analysis
Figure 142: The authors drug assessment summary for Tysabri in multiple sclerosis
Figure 143: The authors drug assessment summary for Tysabri in multiple sclerosis
Figure 144: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 145: Zinbryta for multiple sclerosis – SWOT analysis
Figure 146: The authors drug assessment summary for Zinbryta in multiple sclerosis
Figure 147: The authors drug assessment summary for Zinbryta in multiple sclerosis
Figure 148: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 149: ALKS 8700 for multiple sclerosis – SWOT analysis
Figure 150: The authors drug assessment summary of ALKS 8700 for multiple sclerosis
Figure 151: The authors drug assessment summary of ALKS 8700 for multiple sclerosis
Figure 152: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 153: Ofatumumab for multiple sclerosis – SWOT analysis
Figure 154: The authors drug assessment summary of ofatumumab for multiple sclerosis
Figure 155: The authors drug assessment summary of ofatumumab for multiple sclerosis
Figure 156: Ozanimod for multiple sclerosis – SWOT analysis
Figure 157: The authors drug assessment summary of ozanimod for multiple sclerosis
Figure 158: The authors drug assessment summary of ozanimod for multiple sclerosis
Figure 159: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 160: Ponesimod for multiple sclerosis – SWOT analysis
Figure 161: The authors drug assessment summary of ponesimod for multiple sclerosis
Figure 162: The authors drug assessment summary of ponesimod for multiple sclerosis
Figure 163: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
Figure 164: Siponimod for multiple sclerosis – SWOT analysis
Figure 165: The authors drug assessment summary of siponimod for multiple sclerosis
Figure 166: The authors drug assessment summary of siponimod for multiple sclerosis
Figure 167: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 168: Ublituximab for multiple sclerosis – SWOT analysis
Figure 169: The authors drug assessment summary of ublituximab for multiple sclerosis
Figure 170: The authors drug assessment summary of ublituximab for multiple sclerosis
LIST OF TABLES
Table 1: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 2: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by formulation ($m), 2016–25
Table 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype ($m), 2016–25
Table 4: Multiple sclerosis market treated patient numbers across the US, Japan, and five major EU markets, by disease subtype, 2016–25
Table 5: Sales of the top three highest selling drugs in multiple sclerosis in 2025 across the US, Japan, and five major EU markets ($m), 2016–25
Table 6: Summary of drug classes and molecules included in The authors multiple sclerosis patient-based forecast
Table 7: Exchange rates used for calculating prices
Table 8: Neurologists surveyed for the multiple sclerosis primary research study, 2016
Table 9: ALKS 8700 drug profile
Table 10: ALKS 8700 Phase III trials in multiple sclerosis
Table 11: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
Table 12: Aubagio drug profile
Table 13: Aubagio pivotal trial data in multiple sclerosis
Table 14: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 15: Avonex drug profile
Table 16: Avonex pivotal trial data in multiple sclerosis
Table 17: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 18: Betaseron drug profile
Table 19: Betaseron pivotal trial data in multiple sclerosis
Table 20: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 21: Copaxone drug profile
Table 22: Copaxone pivotal trial data in multiple sclerosis
Table 23: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 24: Gilenya drug profile
Table 25: Gilenya pivotal trial data in multiple sclerosis
Table 26: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 27: Lemtrada drug profile
Table 28: Lemtrada pivotal trial data in multiple sclerosis
Table 29: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 30: Mavenclad drug profile
Table 31: Mavenclad pivotal trial data in multiple sclerosis
Table 32: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 33: Ocrevus drug profile
Table 34: Ocrevus pivotal trial data in multiple sclerosis
Table 35: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 36: Plegridy drug profile
Table 37: Plegridy pivotal trial data in multiple sclerosis
Table 38: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 39: Rebif drug profile
Table 40: Rebif pivotal trial data in multiple sclerosis
Table 41: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 42: Tecfidera drug profile
Table 43: Tecfidera pivotal trial data in multiple sclerosis
Table 44: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 45: Tysabri drug profile
Table 46: Tysabri pivotal trial data in multiple sclerosis
Table 47: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 48: Zinbryta drug profile
Table 49: Zinbryta pivotal trial data in multiple sclerosis
Table 50: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 51: Ofatumumab drug profile
Table 52: Ofatumumab Phase III trials in multiple sclerosis
Table 53: Ozanimod drug profile
Table 54: Ozanimod Phase III data in multiple sclerosis
Table 55: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
Table 56: Ponesimod drug profile
Table 57: Ponesimod Phase III trials in multiple sclerosis
Table 58: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
Table 59: Siponimod drug profile
Table 60: Siponimod Phase III data in multiple sclerosis
Table 61: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 62: Ublituximab drug profile
Table 63: Ublituximab Phase III trials in multiple sclerosis
Table 64: Neurologists surveyed for the multiple sclerosis primary research study, 2016
Table 65: Clinical subtypes of multiple sclerosis
Table 66: Multiple sclerosis diagnostic criteria
Table 67: Primary multiple sclerosis symptoms
Table 68: Leading disease-modifying therapies for multiple sclerosis
Table 69: Commonly used guidelines/consensus papers for the treatment of multiple sclerosis
Table 70: Multiple sclerosis patients treated with disease-modifying therapy in the US, Japan, and five major EU markets, by country (%), 2016
Table 71: Prescription trends in first-line RRMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 72: Prescription trends in second-line and later RRMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 73: Prescription trends in first-line PPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 74: Prescription trends in second-line and later PPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 75: Prescription trends in first-line SPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 76: Prescription trends in second-line and later SPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 77: Mean compliance rates with oral disease-modifying therapies in the US, Japan, and five major EU markets, by disease subtype and country, 2016
Table 78: Mean compliance rates with subcutaneous, injectable disease-modifying therapies, by disease subtype and country, 2016
Table 79: Side effects demonstrated by current multiple sclerosis treatments
Table 80: Sources used for the epidemiological analysis of MS in the US, Japan, and five major EU markets, by country
Table 81: Diagnosed prevalent cases of MS in the US, Japan, and five major EU markets, by country, 2017–37
Table 82: Profiled key marketed drugs for multiple sclerosis
Table 83: Aubagio drug profile
Table 84: Aubagio pivotal trial data in multiple sclerosis
Table 85: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 86: Avonex drug profile
Table 87: Avonex pivotal trial data in multiple sclerosis
Table 88: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 89: Betaseron drug profile
Table 90: Betaseron pivotal trial data in multiple sclerosis
Table 91: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 92: Copaxone drug profile
Table 93: Copaxone pivotal trial data in multiple sclerosis
Table 94: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 95: Gilenya drug profile
Table 96: Gilenya pivotal trial data in multiple sclerosis
Table 97: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 98: Lemtrada drug profile
Table 99: Lemtrada pivotal trial data in multiple sclerosis
Table 100: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 101: Mavenclad drug profile
Table 102: Mavenclad pivotal trial data in multiple sclerosis
Table 103: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 104: Ocrevus drug profile
Table 105: Ocrevus pivotal trial data in multiple sclerosis
Table 106: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 107: Plegridy drug profile
Table 108: Plegridy pivotal trial data in multiple sclerosis
Table 109: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 110: Rebif drug profile
Table 111: Rebif pivotal trial data in multiple sclerosis
Table 112: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 113: Tecfidera drug profile
Table 114: Tecfidera pivotal trial data in multiple sclerosis
Table 115: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 116: Tysabri drug profile
Table 117: Tysabri pivotal trial data in multiple sclerosis
Table 118: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 119: Zinbryta drug profile
Table 120: Zinbryta pivotal trial data in multiple sclerosis
Table 121: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 122: Marketed products and approved indications for multiple sclerosis in the US, Japan, and five major EU markets
Table 123: Levers impacting access to multiple sclerosis drugs in the US and five major EU markets
Table 124: Pricing of key multiple sclerosis drugs in the US, Japan, and five major EU markets, by country
Table 125: Top multiple sclerosis drug prescriptions filled by Medicare beneficiaries participating in Part B and D programs, 2015
Table 126: Multiple sclerosis spend by payers, 2016
Table 127: Specialty drug spend by Express Scripts members, by payer type (multiple sclerosis market), 2016
Table 128: CVS Caremark’s and Express Scripts’ formulary exclusions for multiple sclerosis drugs
Table 129: Formulary placement of multiple sclerosis medications in selected commercial formularies
Table 130: Formulary placement of multiple sclerosis medications in selected Medicare formularies
Table 131: Formulary placement of multiple sclerosis medications, by region
Table 132: Prior authorization criteria for multiple sclerosis drugs in major health insurers and PBMs
Table 133: Multiple sclerosis drug pricing compared to ICER value-price benchmarks
Table 134: Japan – pricing premiums given to medicines that can demonstrate benefit over comparators
Table 135: Price calculation methodologies for multiple sclerosis drugs in Japan launched after 2008
Table 136: Transparency Committee’s ASMR ratings and pricing implications
Table 137: Transparency Committee's SMR ratings and pricing implications
Table 138: Transparency Commission's assessment of multiple sclerosis treatments
Table 139: G-BA assessment of key multiple sclerosis therapies
Table 140: EMA labels and G-BA assessments for Gilenya
Table 141: Reimbursement conditions for multiple sclerosis treatments in Italy
Table 142: Italian regional formulary decisions for multiple sclerosis drugs
Table 143: Therapeutic positioning reports for multiple sclerosis drugs in Spain
Table 144: Spanish Society of Hospital Pharmacy ratings
Table 145: Regional MADRE assessments for multiple sclerosis drugs
Table 146: NICE assessments of key multiple sclerosis therapies
Table 147: UK regional formulary decisions for multiple sclerosis drugs, 2017
Table 148: SMC decisions on key multiple sclerosis therapies
Table 149: Price sources and calculations for the US
Table 150: Price sources and calculations for the EU
Table 151: Exchange rates used for calculating branded drug prices
Table 152: Profiled pipeline products in development for multiple sclerosis
Table 153: ALKS 8700 drug profile
Table 154: ALKS 8700 Phase III trials in multiple sclerosis
Table 155: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
Table 156: Ofatumumab drug profile
Table 157: Ofatumumab Phase III t
Table 2: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by formulation ($m), 2016–25
Table 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype ($m), 2016–25
Table 4: Multiple sclerosis market treated patient numbers across the US, Japan, and five major EU markets, by disease subtype, 2016–25
Table 5: Sales of the top three highest selling drugs in multiple sclerosis in 2025 across the US, Japan, and five major EU markets ($m), 2016–25
Table 6: Summary of drug classes and molecules included in The authors multiple sclerosis patient-based forecast
Table 7: Exchange rates used for calculating prices
Table 8: Neurologists surveyed for the multiple sclerosis primary research study, 2016
Table 9: ALKS 8700 drug profile
Table 10: ALKS 8700 Phase III trials in multiple sclerosis
Table 11: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
Table 12: Aubagio drug profile
Table 13: Aubagio pivotal trial data in multiple sclerosis
Table 14: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 15: Avonex drug profile
Table 16: Avonex pivotal trial data in multiple sclerosis
Table 17: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 18: Betaseron drug profile
Table 19: Betaseron pivotal trial data in multiple sclerosis
Table 20: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 21: Copaxone drug profile
Table 22: Copaxone pivotal trial data in multiple sclerosis
Table 23: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 24: Gilenya drug profile
Table 25: Gilenya pivotal trial data in multiple sclerosis
Table 26: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 27: Lemtrada drug profile
Table 28: Lemtrada pivotal trial data in multiple sclerosis
Table 29: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 30: Mavenclad drug profile
Table 31: Mavenclad pivotal trial data in multiple sclerosis
Table 32: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 33: Ocrevus drug profile
Table 34: Ocrevus pivotal trial data in multiple sclerosis
Table 35: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 36: Plegridy drug profile
Table 37: Plegridy pivotal trial data in multiple sclerosis
Table 38: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 39: Rebif drug profile
Table 40: Rebif pivotal trial data in multiple sclerosis
Table 41: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 42: Tecfidera drug profile
Table 43: Tecfidera pivotal trial data in multiple sclerosis
Table 44: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 45: Tysabri drug profile
Table 46: Tysabri pivotal trial data in multiple sclerosis
Table 47: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 48: Zinbryta drug profile
Table 49: Zinbryta pivotal trial data in multiple sclerosis
Table 50: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 51: Ofatumumab drug profile
Table 52: Ofatumumab Phase III trials in multiple sclerosis
Table 53: Ozanimod drug profile
Table 54: Ozanimod Phase III data in multiple sclerosis
Table 55: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
Table 56: Ponesimod drug profile
Table 57: Ponesimod Phase III trials in multiple sclerosis
Table 58: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
Table 59: Siponimod drug profile
Table 60: Siponimod Phase III data in multiple sclerosis
Table 61: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 62: Ublituximab drug profile
Table 63: Ublituximab Phase III trials in multiple sclerosis
Table 64: Neurologists surveyed for the multiple sclerosis primary research study, 2016
Table 65: Clinical subtypes of multiple sclerosis
Table 66: Multiple sclerosis diagnostic criteria
Table 67: Primary multiple sclerosis symptoms
Table 68: Leading disease-modifying therapies for multiple sclerosis
Table 69: Commonly used guidelines/consensus papers for the treatment of multiple sclerosis
Table 70: Multiple sclerosis patients treated with disease-modifying therapy in the US, Japan, and five major EU markets, by country (%), 2016
Table 71: Prescription trends in first-line RRMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 72: Prescription trends in second-line and later RRMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 73: Prescription trends in first-line PPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 74: Prescription trends in second-line and later PPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 75: Prescription trends in first-line SPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 76: Prescription trends in second-line and later SPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
Table 77: Mean compliance rates with oral disease-modifying therapies in the US, Japan, and five major EU markets, by disease subtype and country, 2016
Table 78: Mean compliance rates with subcutaneous, injectable disease-modifying therapies, by disease subtype and country, 2016
Table 79: Side effects demonstrated by current multiple sclerosis treatments
Table 80: Sources used for the epidemiological analysis of MS in the US, Japan, and five major EU markets, by country
Table 81: Diagnosed prevalent cases of MS in the US, Japan, and five major EU markets, by country, 2017–37
Table 82: Profiled key marketed drugs for multiple sclerosis
Table 83: Aubagio drug profile
Table 84: Aubagio pivotal trial data in multiple sclerosis
Table 85: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 86: Avonex drug profile
Table 87: Avonex pivotal trial data in multiple sclerosis
Table 88: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 89: Betaseron drug profile
Table 90: Betaseron pivotal trial data in multiple sclerosis
Table 91: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 92: Copaxone drug profile
Table 93: Copaxone pivotal trial data in multiple sclerosis
Table 94: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 95: Gilenya drug profile
Table 96: Gilenya pivotal trial data in multiple sclerosis
Table 97: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 98: Lemtrada drug profile
Table 99: Lemtrada pivotal trial data in multiple sclerosis
Table 100: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 101: Mavenclad drug profile
Table 102: Mavenclad pivotal trial data in multiple sclerosis
Table 103: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 104: Ocrevus drug profile
Table 105: Ocrevus pivotal trial data in multiple sclerosis
Table 106: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 107: Plegridy drug profile
Table 108: Plegridy pivotal trial data in multiple sclerosis
Table 109: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 110: Rebif drug profile
Table 111: Rebif pivotal trial data in multiple sclerosis
Table 112: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 113: Tecfidera drug profile
Table 114: Tecfidera pivotal trial data in multiple sclerosis
Table 115: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 116: Tysabri drug profile
Table 117: Tysabri pivotal trial data in multiple sclerosis
Table 118: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 119: Zinbryta drug profile
Table 120: Zinbryta pivotal trial data in multiple sclerosis
Table 121: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 122: Marketed products and approved indications for multiple sclerosis in the US, Japan, and five major EU markets
Table 123: Levers impacting access to multiple sclerosis drugs in the US and five major EU markets
Table 124: Pricing of key multiple sclerosis drugs in the US, Japan, and five major EU markets, by country
Table 125: Top multiple sclerosis drug prescriptions filled by Medicare beneficiaries participating in Part B and D programs, 2015
Table 126: Multiple sclerosis spend by payers, 2016
Table 127: Specialty drug spend by Express Scripts members, by payer type (multiple sclerosis market), 2016
Table 128: CVS Caremark’s and Express Scripts’ formulary exclusions for multiple sclerosis drugs
Table 129: Formulary placement of multiple sclerosis medications in selected commercial formularies
Table 130: Formulary placement of multiple sclerosis medications in selected Medicare formularies
Table 131: Formulary placement of multiple sclerosis medications, by region
Table 132: Prior authorization criteria for multiple sclerosis drugs in major health insurers and PBMs
Table 133: Multiple sclerosis drug pricing compared to ICER value-price benchmarks
Table 134: Japan – pricing premiums given to medicines that can demonstrate benefit over comparators
Table 135: Price calculation methodologies for multiple sclerosis drugs in Japan launched after 2008
Table 136: Transparency Committee’s ASMR ratings and pricing implications
Table 137: Transparency Committee's SMR ratings and pricing implications
Table 138: Transparency Commission's assessment of multiple sclerosis treatments
Table 139: G-BA assessment of key multiple sclerosis therapies
Table 140: EMA labels and G-BA assessments for Gilenya
Table 141: Reimbursement conditions for multiple sclerosis treatments in Italy
Table 142: Italian regional formulary decisions for multiple sclerosis drugs
Table 143: Therapeutic positioning reports for multiple sclerosis drugs in Spain
Table 144: Spanish Society of Hospital Pharmacy ratings
Table 145: Regional MADRE assessments for multiple sclerosis drugs
Table 146: NICE assessments of key multiple sclerosis therapies
Table 147: UK regional formulary decisions for multiple sclerosis drugs, 2017
Table 148: SMC decisions on key multiple sclerosis therapies
Table 149: Price sources and calculations for the US
Table 150: Price sources and calculations for the EU
Table 151: Exchange rates used for calculating branded drug prices
Table 152: Profiled pipeline products in development for multiple sclerosis
Table 153: ALKS 8700 drug profile
Table 154: ALKS 8700 Phase III trials in multiple sclerosis
Table 155: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
Table 156: Ofatumumab drug profile
Table 157: Ofatumumab Phase III t
